Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies

NCT05735717 is registered in ClinicalTrials.gov with Masonic Cancer Center, University of Minnesota as lead sponsor.

NCT NCT05735717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05735717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies
Lead sponsor
Masonic Cancer Center, University of Minnesota
Phase
Phase 2
Overall status
Recruiting
Start date
May 11, 2023
Completion date
November 30, 2030
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, aml, cbl gene mutation, chromosome abnormality, cns leukemia, cytogenetic abnormality, fetal hemoglobin, hematologic malignancy, high grade non-hodgkin's lymphoma, adult, intrachromosomal amplification of chromosome 21, juvenile myelomonocytic leukemia, lymphoblastic lymphoma, minimal residual disease, monosomy 7, myelodysplasia, n-ras gene amplification, neurofibromatosis 1, nf1 mutation, ptpn11 gene mutation, remission, somatic mutation, tp53